KCM
Kynam Capital Management Portfolio holdings
AUM
$929M
This Quarter Return
-8%
1 Year Return
-7.66%
3 Year Return
+163.82%
5 Year Return
–
10 Year Return
–
AUM
$602M
AUM Growth
+$602M
(-7.8%)
Cap. Flow
+$69.7M
Cap. Flow
% of AUM
11.58%
Top 10 Holdings %
Top 10 Hldgs %
83.15%
Holding
32
New
5
Increased
15
Reduced
5
Closed
1
Top Buys
| 1 |
Celldex Therapeutics
CLDX
|
$16.5M |
| 2 |
Protagonist Therapeutics
PTGX
|
$14.1M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$12.2M |
| 4 |
Taysha Gene Therapies
TSHA
|
$10.4M |
| 5 |
Dynavax Technologies
DVAX
|
$7.39M |
Top Sells
| 1 |
Olema Pharmaceuticals
OLMA
|
$13.2M |
| 2 |
Travere Therapeutics
TVTX
|
$4.45M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$1.53M |
| 4 |
Vera Therapeutics
VERA
|
$603K |
| 5 |
Neurogene
NGNE
|
$379K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $133M | 21.74% | 3,003,668 +103,668 | +4% | +$4.59M |
|
|
2
Celldex Therapeutics
CLDX
$1.47B
| $88.1M | 14.4% | 3,200,000 +600,000 | +23% | +$16.5M |
|
3
Vaxcyte
PCVX
$4B
| $66.4M | 10.86% | 1,302,407 +2,407 | +0.2% | +$123K |
|
4
Syndax Pharmaceuticals
SNDX
$1.41B
| $52.3M | 8.55% | 3,600,000 +337,996 | +10% | +$4.91M |
|
|
5
Vera Therapeutics
VERA
$1.38B
| $40.5M | 6.63% | 2,956,053 -43,947 | -1% | -$603K |
|
|
6
Protagonist Therapeutics
PTGX
$3.67B
| $30.3M | 4.96% | 1,818,657 +843,359 | +86% | +$14.1M |
|
|
TSVT
7
DELISTED
2seventy bio
TSVT
| $23.3M | 3.82% | 5,953,825 +1,063,119 | +22% | +$4.17M |
|
8
Wave Life Sciences
WVE
$1.53B
| $22.6M | 3.7% | 3,932,082 +7,480 | +0.2% | +$43K |
|
9
BioCryst Pharmaceuticals
BCRX
$1.74B
| $22.2M | 3.63% | 3,133,193 +284,996 | +10% | +$2.02M |
|
10
Cogent Biosciences
COGT
$1.69B
| $21.5M | 3.52% | 2,210,125 +592,734 | +37% | +$5.78M |
|
11
Liquidia Corp
LQDA
$2.38B
| $12.7M | 2.07% | 2,000,000 +357,756 | +22% | +$2.27M |
|
|
SLRN
12
DELISTED
ACELYRIN
SLRN
| $12.2M | 2% | +1,200,000 | New | +$12.2M |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $11.1M | 1.81% | 12,022,957 +22,957 | +0.2% | +$21.1K |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $10.7M | 1.76% | 699,681 -9,817 | -1% | -$151K |
|
|
15
Taysha Gene Therapies
TSHA
$797M
| $10.4M | 1.7% | +3,281,313 | New | +$10.4M |
|
|
16
Travere Therapeutics
TVTX
$1.56B
| $8.56M | 1.4% | 957,502 -497,228 | -34% | -$4.45M |
|
|
BNR
17
Burning Rock Biotech
BNR
$93.6M
| $8.25M | 1.35% | 8,500,000 | – | – |
|
|
18
Dynavax Technologies
DVAX
$1.19B
| $7.39M | 1.21% | +500,000 | New | +$7.39M |
|
19
Sutro Biopharma
STRO
$72.7M
| $5.39M | 0.88% | 1,552,675 +52,675 | +4% | +$183K |
|
20
Caribou Biosciences
CRBU
$174M
| $5.11M | 0.84% | +1,068,527 | New | +$5.11M |
|
|
CNTA
21
Centessa Pharmaceuticals
CNTA
$2.25B
| $4.73M | 0.77% | 730,472 +1,395 | +0.2% | +$9.03K |
|
|
22
Olema Pharmaceuticals
OLMA
$375M
| $2.9M | 0.48% | 235,176 -1,069,156 | -82% | -$13.2M |
|
23
Puma Biotechnology
PBYI
$254M
| $1.25M | 0.2% | 473,975 +905 | +0.2% | +$2.38K |
|
|
CNTB
24
Connect Biopharma
CNTB
$115M
| $434K | 0.07% | 535,005 | – | – |
|
25
Gossamer Bio
GOSS
$562M
| $208K | 0.03% | +250,000 | New | +$208K |
|